A Multicenter Experience With Infliximab for Ulcerative Colitis: Outcomes and Predictors of Response, Optimization, Colectomy, and Hospitalization

Oussalah, Abderrahim; Evesque, Ludovic; Laharie, David; Roblin, Xavier; Boschetti, Gilles; Nancey, Stéphane; Filippi, Jérôme; Flourié, Bernard; Hebuterne, Xavier; Bigard, Marc-André; Peyrin-Biroulet, Laurent
December 2010
American Journal of Gastroenterology;Dec2010, Vol. 105 Issue 12, p2617
Academic Journal
OBJECTIVES:The objective of this study was to evaluate short- and long-term outcomes of infliximab in ulcerative colitis (UC), including infliximab optimization, colectomy, and hospitalization.METHODS:This was a retrospective multicenter study. All adult patients who received at least one infliximab infusion for UC were included. Cumulative probabilities of event-free survival were estimated by the Kaplan-Meier method. Independent predictors were identified using binary logistic regression or Cox proportional-hazards regression, and results were expressed as odds ratios or hazard ratios (HRs), respectively.RESULTS:Between January 2000 and August 2009, 191 UC patients received infliximab therapy. Median follow-up per patient was 18 months (interquartile range=25-75th, 8-32 months). Primary non-response was noted in 42 patients (22.0%). 'Hemoglobin at infliximab initiation ≤9.4 g/dl' (odds ratio=4.35; 95% confidence interval (CI)=1.81-10.42) was a positive predictor of non-response to infliximab. Infliximab optimization was required in 36 (45.0%) of 80 patients on scheduled infliximab therapy. The only predictor of infliximab optimization was 'infliximab indication for acute severe colitis' (HR=2.75; 95% CI=1.23-6.12). Thirty-six patients (18.8%) underwent colectomy. Predictors of colectomy were: 'no clinical response after infliximab induction' (HR=7.06; 95% CI=3.36-14.83), 'C-reactive protein at infliximab initiation >10 mg/l' (HR=5.11; 95% CI=1.77-14.76), 'infliximab indication for acute severe colitis' (HR=3.40; 95% CI=1.48-7.81), and 'previous treatment with cyclosporine' (HR=2.53; 95% CI=1.22-5.28). Sixty-nine patients (36.1%) were hospitalized at least one time and UC-related hospitalizations rate was 29 per 100 patient-years (95% CI=24-35 per 100 patient-years). Predictors of first hospitalization were: 'no clinical response after infliximab induction' (HR=3.87; 95% CI=2.29-6.53), 'infliximab indication for acute severe colitis' (HR=3.13, 95% CI=1.65-5.94), 'disease duration at infliximab initiation ≤50 months' (HR=2.14, 95% CI=1.25-3.66), 'hemoglobin at infliximab initiation ≤11.8 g/dl' (HR=1.77; 95% CI=1.03-3.04), and 'previous treatment with methotrexate' (HR=0.30; 95% CI=0.09-0.97).CONCLUSIONS:Primary non-response to infliximab was noted in one fifth of patients and increased by seven and four the risks of colectomy and hospitalization, respectively. Infliximab optimization, colectomy, and hospitalization were required in half, one fifth, and one third of patients, respectively. Infliximab indication for acute severe colitis increased by three the risks of infliximab optimization, colectomy, and UC-related hospitalization.


Related Articles

  • Clinical trial: colectomy after rescue therapy in ulcerative colitis-- 3-year follow-up of the Swedish--Danish controlled infliximab study.  // Inflammatory Bowel Disease Monitor;2011, Vol. 11 Issue 3, p130 

    The article presents a study on the use of infliximab as rescue therapy in acute, severe ulcerative colitis (UC) in Sweden and Denmark. It notes that colectomy rates at three months were 29.2% for infliximab recipients and 66.6% for placebo recipients. Moreover, the three year colectomy rate for...

  • Does the Cyclosporine Still Have a Potential Role in the Treatment of Acute Severe Steroid-Refractory Ulcerative Colitis? Chang Soo Eun; Dong Soo Han // Gut & Liver;Sep2015, Vol. 9 Issue 5, p567 

    The article discusses a study which investigated the efficacy of cyclosporine and infliximab in 43 patients with severe steroid-refractory ulcerative colitis (UC) in a retrospective manner. It relates a justification for a prospective multicenter randomized clinical trial comparing the efficacy...

  • Value of colonoscopy for prediction of prognosis in patients with ulcerative colitis. Ando, Takafumi; Nishio, Yuji; Watanabe, Osamu; Takahashi, Hironao; Maeda, Osamu; Ishiguro, Kazuhiro; Ishikawa, Daisuke; Ohmiya, Naoki; Niwa, Yasumasa; Goto, Hidemi; Rodrigo, Luis; Vandenplas, Yvan // World Journal of Gastroenterology;4/14/2008, Vol. 14 Issue 14, p2133 

    Ulcerative colitis (UC) is a chronic inflammatory bowel disorder characterized by exacerbations and remissions. Some UC patients remain refractory to conventional medical treatment while, in others, the effectiveness of drugs is limited by side-effects. Recently, cyclosporine and leukocyte...

  • Intravenous Cyclosporin in Ulcerative Colitis: A Five-Year Experience. Cohen, Russell D.; Stein, Robert; Hanauer, Stephen B. // American Journal of Gastroenterology;Jun1999, Vol. 94 Issue 6, p1587 

    OBJECTIVE: Cyclosporin (CSA) is a promising alternative for patients with severe steroid-refractory ulcerative colitis (UC) previously facing only surgical options. Concerns over the long term efficacy and side effects resulted in this investigation of the University of Chicago's 5-yr CSA...

  • Anti-TNF approved for severe ulcerative colitis in children.  // British Journal of Hospital Medicine (17508460);Apr2012, Vol. 73 Issue 4, p189 

    The article reports that Infliximab (Remicade) is indicated for treating severely active ulcerative colitis in patients aged 6-17 years, who have had a poor response to conventional therapy or are intolerant to or have contraindications for these therapies.

  • Infliximab.  // Reactions Weekly;Sep2015, Vol. 1569 Issue 1, p131 

    The article presents case studies of three patients with history of ulcerative colitis who developed acute bullous dermatosis epileptic seizure or varicella zoster virus reactivation while having treatment with infliximab.

  • Infliximab.  // Reactions Weekly;Sep2015, Vol. 1569 Issue 1, p130 

    The article presents a case study of a 38-year-old woman with a history of refractory ulcerative colitis who developed fulminant hepatic failure after receiving therapy with infliximab infusion.

  • Infliximab/Meprednisone.  // Reactions Weekly;2/6/2016, Vol. 1587 Issue 1, p164 

    An abstract of the article "A very late onset of ulcerative colitis" by M. Izzy and others is presented.

  • Thalidomide as rescue therapy for acute severe ulcerative colitis. DIAMANTI, A.; KNAFELZ, D.; PANETTA, F.; DE ANGELIS, P.; CANDUSSO, M.; BRACCI, F.; PAPADATOU, B.; FRANCALANCI, P.; MONTI, L.; TORRE, G. // European Review for Medical & Pharmacological Sciences;Jun2014, Vol. 18 Issue 12, p1690 

    INTRODUCTION: Acute severe exacerbations of Ulcerative Colitis (UC) represent a medical emergency in children and adults. Intravenous steroids remain the first line therapy for this condition, although the steroid refractoriness is common. Second-line therapy, based on the infliximab or...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics